![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ALTACHEM RECEIVES CLEARANCE TO BEGIN PHASE I TRIAL
ALTACHEM RECEIVES CLEARANCE TO BEGIN PHASE I TRIAL
September 2, 2005
Altachem Pharma has received clearance from the Therapeutic Products Directorate of Health Canada to initiate a Phase I clinical trial to investigate the topical application of its lead photodynamic therapy (PDT) compound ACP-SL017 as a treatment for actinic keratosis, a potentially serious precancerous skin condition.
This clinical trial is a controlled, randomized, open-label, dose-escalation study for the topical application of ACP-SL017 topical gel to patients with the condition. The study is designed to determine the cutaneous and systemic toxicity of topically applied ACP-SL017 with and without photoactivation, and to evaluate clinically and pathologically the therapeutic effect of applying PDT to actinic keratosis using photoactivated ACP-SL017.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct